ADMA Biologics Inc
NASDAQ:ADMA

Watchlist Manager
ADMA Biologics Inc Logo
ADMA Biologics Inc
NASDAQ:ADMA
Watchlist
Price: 17.42 USD 0.11%
Market Cap: 4.1B USD
Have any thoughts about
ADMA Biologics Inc?
Write Note

ADMA Biologics Inc
Pre-Tax Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

ADMA Biologics Inc
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
ADMA Biologics Inc
NASDAQ:ADMA
Pre-Tax Income
$73.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Pre-Tax Income
$7.2B
CAGR 3-Years
0%
CAGR 5-Years
19%
CAGR 10-Years
4%
Gilead Sciences Inc
NASDAQ:GILD
Pre-Tax Income
$176m
CAGR 3-Years
-73%
CAGR 5-Years
-47%
CAGR 10-Years
-34%
Amgen Inc
NASDAQ:AMGN
Pre-Tax Income
$4.7B
CAGR 3-Years
-10%
CAGR 5-Years
-13%
CAGR 10-Years
-1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Pre-Tax Income
$259.6m
CAGR 3-Years
-54%
CAGR 5-Years
-19%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Pre-Tax Income
$5B
CAGR 3-Years
-15%
CAGR 5-Years
18%
CAGR 10-Years
21%
No Stocks Found

ADMA Biologics Inc
Glance View

Market Cap
4.1B USD
Industry
Biotechnology

ADMA Biologics Inc. operates at the intersection of biotechnology and pharmaceuticals with a dedicated focus on the development and commercialization of plasma-based therapeutics. Established with a mission to address unmet medical needs, particularly in immune-compromised patients, ADMA leverages its specialized expertise in the collection, manufacturing, and distribution of immunoglobulins. The company owns and operates FDA-approved source plasma collection facilities under the name ADMA BioCenters, which supply plasma as a key raw material. This plasma serves as the foundation for their suite of FDA-approved products aimed at treating immune deficiencies and other related disorders. Central to ADMA's business model is its vertically integrated approach, which enables the company to maintain stringent oversight from plasma collection to product development and distribution. By controlling the entire supply chain, ADMA can achieve cost efficiencies and ensure high-quality standards, crucial for patient safety and regulatory compliance. The company generates revenue primarily through the sale of its flagship products, such as BIVIGAM and ASCENIV, which are used for immune globulin replacement therapy. ADMA also broadens its revenue streams through strategic partnerships and by offering third-party contract manufacturing services. This diversified approach positions the company robustly within the competitive biopharmaceutical landscape, while striving for growth through research and development of new plasma-derived therapies.

ADMA Intrinsic Value
10.52 USD
Overvaluation 40%
Intrinsic Value
Price

See Also

What is ADMA Biologics Inc's Pre-Tax Income?
Pre-Tax Income
73.4m USD

Based on the financial report for Sep 30, 2024, ADMA Biologics Inc's Pre-Tax Income amounts to 73.4m USD.

Back to Top